MEET YOUR NEW AI CLINICAL ASSISTANT /// GET EARLY ACCESS
Tempus, a leader in artificial intelligence and precision medicine, today announced eleven abstracts accepted for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4 - 8. “These high impact ASCO presentations from Tempus collaborators and investigators illustrate the power of over 35 pe...
Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of its cloud-based data and analytics platform, Lens. The all-in-one platform will provide scientists and researchers across biotechnology and pharmaceutical companies with short term, on demand access to more than 35 petabytes of de-identified cli...
Five real-world data (RWD) and analytics organizations today announced an industry coalition dedicated to advancing the use of real-world evidence (RWE) to support regulatory decisions. Founding members of the RWE Alliance are Aetion, Flatiron Health, IQVIA, Syapse, and Tempus. The RWE Alliance intends t...
From the beginning of the pandemic, health experts were concerned that millions of Americans would defer treatment of existing illnesses—including cancer—and postpone routine preventative screenings given the justifiable fear of contracting COVID-19. Now, more than a year after COVID-19 forced the country to a complete halt, a clearer picture is starting to eme...
Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will convene virtually on April 10-15 and May 17-21. The research leverages Tempus’ unparalleled library of multi-modal data to facilitate discovery, development, and delivery of opt...
Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of the Tempus iC Home Collection (1), a COVID-19 test with unsupervised self-collection at home. Physicians can now order the Tempus iC Home Collection test for eligible patients and have the collection kits shipped to their homes for unsupervised self-collection at...
Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atr...
Community Health Network announced today it is collaborating with Tempus, a leader in precision medicine and artificial intelligence, to improve patient health and outcomes through genomic testing. Among a variety of precision medicine solutions, Tempus offers a suite of oncology-focused genomic testing and targeted clinical trial matching. The...
A team of scientists from Geisinger and Tempus have found that artificial intelligence can predict risk of new atrial fibrillation (AF) and AF-related stroke. Atrial fibrillation is the most common cardiac arrhythmia and is associated with numerous health risks, including stroke and death. The study, published in Circulation, used el...
Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigational CDK9 inhibitor. Tempus will use its xT broad-panel genomic assay to provide retrospective sequenc...